What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? - Considerations on pre-analytical aspects by the IFCC workgroup cfDNA

R Danesi; Y M D Lo; M Oellerich; J Beck; S Galbiati; M Del Re; E Lianidou; M Neumaier; R H N van Schaik

doi:10.1016/j.cca.2021.05.033

What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? - Considerations on pre-analytical aspects by the IFCC workgroup cfDNA

Clin Chim Acta. 2021 Sep:520:168-171. doi: 10.1016/j.cca.2021.05.033. Epub 2021 Jun 1.

Authors

R Danesi¹, Y M D Lo², M Oellerich³, J Beck⁴, S Galbiati⁵, M Del Re¹, E Lianidou⁶, M Neumaier⁷, R H N van Schaik⁸

Affiliations

¹ Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
² Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China.
³ Dept. Clinical Pharmacology, George-August University, University Medical Center Goettingen, Goettingen, Germany.
⁴ Chronix BioMedical GmbH, Goettingen, Germany.
⁵ Unit of Genomic for the Diagnosis of Human Pathologies, Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁶ Dept. Chemistry, University of Athens, Athens, Greece.
⁷ Institute for Clinical Chemistry, Mannheim, Germany.
⁸ Dept. Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: [email protected].

PMID: 34081934
DOI: 10.1016/j.cca.2021.05.033

Abstract

The analysis of circulating cell free DNA is an important tool for the analysis of tumor resistance, tumor heterogeneity, detection of minimal residual disease and detection of allograft rejection in kidney or heart transplant patients. The proper use of this technique is important, and starts with considering pre-analytic aspects. The current paper addresses some important technical considerations to ensure the proper and harmonized use of cfDNA techniques.

Keywords: Liquid biopsy; NCSLC; Technical aspects; cfDNA; ctDNA; pre-analytical factors.

MeSH terms

Biomarkers, Tumor / genetics
Cell-Free Nucleic Acids*
Circulating Tumor DNA* / genetics
Diagnostic Tests, Routine
Humans
Neoplasm, Residual

Substances

Biomarkers, Tumor
Cell-Free Nucleic Acids
Circulating Tumor DNA